| Date | Subject | Details |
|---|---|---|
| 2023/12/20 | Update on the progress of the investigator-initiated phase 2 clinical trial of new drug OBP-301 in the United States | 20231220 |
| 2023/12/13 | The Ministry of Health and Welfare has approved the collaborative autologous Natural Killer cell therapy project by the Company and Show Chwan Memorial Hospital | 20231213 |
| 2023/12/08 | The cumulative securities disposed by the Company have reached the announcement threshold | 20231208 |
| 2023/12/07 | The company was invited to participate in the investor conference held by SinoPac Securities | 20231207-2 |
| 2023/12/07 | The Ministry of Health and Welfare has approved the collaborative autologous Natural Killer cell therapy project by the Company and Chang Bing Show Chwan Hospital | 20231207-1 |
| 2023/12/01 | The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Hualien Tzu Chi Hospital | 20231201 |
| 2023/11/07 | Change of Internal Audit Officer of the Company | 20231107-3 |
| 2023/11/07 | The Company’s 2023 Q3 consolidated financial statements have been approved by the Board of Directors | 20231107-2 |
| 2023/11/07 | Results of Phase II clinical trial of OBP-301 presented in the Society for Immunotherapy of Cancer (SITC) | 20231107-1 |
| 2023/10/24 | The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Chang Bing Show Chwan Memorial Hospital | 20231024 |
| 2023/10/16 | Announcement on Topline Data Results from Phase II Clinical Trial evaluating OBP-301 for Esophageal Cancer in Japan | 20231016 |
| 2023/09/25 | Update on the development status of New Drug OBP-301 | 20230925 |
| 2023/09/13 | The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Show Chwan Memorial Hospital | 20230913 |
| 2023/08/10 | Results of Phase I PI-initiated clinical trial in the United States of OBP-301 combined with chemoradiotherapy for the treatment of esophageal cancer | 20230810 |
| 2023/08/08 | The Company’s 2023 Q2 consolidated financial statements have been approved by the Board of Directors | 20230808 |
| 2023/08/04 | The Company’s capital amendment registration has been completed due to the cancellation of the New Restricted Employee Shares. | 20230804 |
| 2023/08/01 | Announcement on behalf of the Company’s major subsidiary TBG Diagnostics Ltd. regarding the list of directors elected at 2023 Annual Shareholders’ Meeting | 20230801-2 |
| 2023/08/01 | Announcement on behalf of the Company’s major subsidiary TBG Diagnostics Ltd. regarding resolutions of 2023 Annual Shareholders’ Meeting | 20230801-1 |
| 2023/07/03 | Announcement on behalf of the Company’s major subsidiary TBG Diagnostics Ltd. regarding the convention of the general shareholders meeting (Add new proposal) | 20230703 |
| 2023/06/29 | Announcement on behalf of the Company’s major subsidiary TBG Diagnostics Ltd. regarding the convention of the general shareholders meeting | 20230629 |
| 2023/06/26 | The Company’s Board Resolution to Redeem the Restricted Stocks to Employees | 20230626-7 |
| 2023/06/26 | Change of the Company’s important operating managers | 20230626-6 |
| 2023/06/26 | Change of the Company’s General Manager | 20230626-5 |
| 2023/06/26 | Additional member appointed to the Company’s Audit Committee and Remuneration Committee | 20230626-4 |
| 2023/06/26 | 2023 Annual Shareholders’ Meeting has approved to remove the restrictions on non-competition for newly appointed independent director | 20230626-3 |
| 2023/06/26 | Additional Independent Director elected at the Company’s 2023 Annual Shareholder’s Meeting | 20230626-2 |
| 2023/06/26 | Important Resolutions of 2023 Annual Shareholders’ Meeting of the Company | 20230626-1 |
| 2023/06/06 | Results of Phase II clinical trial of OBP-301 presented at the American Society of Clinical Oncology (ASCO) | 20230606 |
| 2023/05/31 | The Company’s Board of Directors has resolved not to issue dividends (Amendment to 2023/3/30 announcement due to typo) | 20230531-2 |
| 2023/05/31 | The Ministry of Health and Welfare has approved the collaborative autologous Natural Killer cell therapy project by the Company and MacKay Memorial Hospital | 20230531-1 |
| 2023/05/26 | The company’s Board of Directors has resolved to replace the accounting firm and the certified public accountants | 20230526 |
| 2023/05/08 | The Company’s 2023 Q1 consolidated financial statements have been approved by the Board of Directors | 20230508 |
| 2023/04/11 | Correction of the disclosed amounts of related-party transactions occurred in November and December 2022 | 20230411 |
| 2023/03/30 | The Company’s 2022 consolidated financial statements have been reported to the Board of Directors | 20230330-2 |
| 2023/03/30 | The Company’s Board of Directors has resolved not to issue dividends | 20230330-1 |
| 2023/03/28 | The Company’s Board of Directors Resolution to convene 2023 Annual Shareholder’s Meeting | 20230328 |
| 2023/02/20 | The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Shin Kong Wu Ho-Su Memorial Hospital | 20230220 |
